Anito-cel Phase One Results Published

Company Arcellx / Gilead (Kite) Event Type Peer-Reviewed Clinical Data Modality CAR-T Cell Therapy (Synthetic d-Domain Binder) Asset Anitocabtagene Autoleucel (Anito-cel) Target BCMA Disease Area Relapsed or Refractory Multiple Myeloma Summary A peer-reviewed Phase 1 study of anitocabtagene autoleucel reported responses in all 38 treated…